[1]
|
Bergethon, K., Shaw, A.T., Ou, S.H., Katayama, R., Lovly, C.M., McDonald, N.T., Massion, P.P., Siwak-Tapp, C., Gonzalez, A., Fang, R., Mark, E.J., Batten, J.M., Chen, H., Wilner, K.D., Kwak, E.L., Clark, J.W., Carbone, D.P., Ji, H., Engelman, J.A., Mino-Kenudson, M., Pao, W. and Iafrate, A.J. (2012) ROS1 Rearrangements Define Aunique Molecular Class of Lung Cancers. Journal of Clinical Oncology, 30, 863-870. https://doi.org/10.1200/JCO.2011.35.6345
|
[2]
|
Carotenuto, P., Roma, C., Rachiglio, A.M., Botti, G., D’Alessio, A. and Normanno, N. (2010) Triple Negative Breast Cancer: From Molecular Portrait to Therapeutic Intervention. Critical Reviews in Eukaryotic Gene Expression, 20, 17-34.
|
[3]
|
Carotenuto, P., Roma, C., Rachiglio, A.M., Tatangelo, F., Pinto, C., Ciardiello, F., Nappi, O., Iaffaioli, R.V., Botti, G. and Normanno, N. (2010) Detection of KRAS Mutations in Colorectal Carcinoma Patients with an Integrated PCR/Sequencing and Real-Time PCR Approach. Pharmacogenomics, 11, 1169-1179.
|
[4]
|
Carvajal, R.D., Antonescu, C.R., Wolchok, J.D., Chapman, P.B., Roman, R.A., Teitcher, J., Panageas, K.S., Busam, K.J., Chmielowski, B., Lutzky, J., Pavlick, A.C., Fusco, A., Cane, L., Takebe, N., Vemula, S., Bouvier, N., Bastian, B.C. and Schwartz, G.K. (2011) KIT as a Therapeutic Target in Metastatic Melanoma. JAMA, 305, 2327-2334. https://doi.org/10.1001/jama.2011.746
|
[5]
|
Chapman, P.B., Hauschild, A., Robert, C., Haanen, J.B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., Hogg, D., Lorigan, P., Lebbe, C., Jouary, T., Schadendorf, D., Ribas, A., O’Day, S.J., Sosman, J.A., Kirkwood, J.M., Eggermont, A.M.M., Dreno, B., Nolop, K., Li, J., Nelson, B., Hou, J., Lee, R.J., Flaherty, K.T. and McArthur, G.A. (2011) Improved Survival with Vemurafenib in Melanoma with BRAFV600E Mutation. The New England Journal of Medicine, 364, 2507-2516. https://doi.org/10.1056/NEJMoa1103782
|
[6]
|
De Luca, A. and Normanno, N. (2010) Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer. Current Drug Targets, 11, 851-864. https://doi.org/10.2174/138945010791320773
|
[7]
|
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K.T., Kotoula, V., Papamichael, D., Laurent-Puig, P., Penault-Llorca, F., Rougier, P., Vincenzi, B., Santini, D., Tonini, G., Cappuzzo, F., Frattini, M., Molinari, F., Saletti, P., De Dosso, S., Martini, M., Bardelli, A., Siena, S., Sartore-Bianchi, A., Tabernero, J., Macarulla, T., Di Fiore, F., Gangloff, A.O., Ciardiello, F., Pfeiffer, P., Qvortrup, C., Hansen, T.P., Van Cutsem, E., Piessevaux, H., Lambrechts, D., Delorenzi, M. and Tejpar, S. (2010) Effects of KRAS, BRAF, NRAS, and PIK3C Amutations on the Efficacy of Cetuximab plus Chemotherapy in Chemotherapy-Refractory Metastatic Colorectal Cancer: A Retrospective Consortium Analysis. The Lancet Oncology, 11, 753-762.
|
[8]
|
De Roock, W., De Vriendt, V., Normanno, N., Ciardiello, F. and Tejpar, S. (2010) KRAS, BRAF, PIK3CA, and PTEN Mutations: Implications for Targeted Therapies Inmetastatic Colorectal Cancer. The Lancet Oncology, 12, 594-603.
|
[9]
|
De Roock, W., Jonker, D.J., Di Nicolantonio, F., Sar-tore-Bianchi, A., Tu, D., Siena, S., Lamba, S., Arena, S., Frattini, M., Piessevaux, H., Van Cutsem, E., O’Callaghan, C.J., Khambata-Ford, S., Zalcberg, J.R., Simes, J., Karapetis, C.S., Bardelli, A. and Tejpar, S. (2010) Association of KRAS p.G13D Mutation with Outcome in Patients with Chemotherapy-Refractory Metastatic Colorectal Cancer Treated with Cetuximab. JAMA, 304, 1812-1820.
|
[10]
|
Diaz, L.A., Williams, R.T., Wu, J., Kinde, I., Hecht, J.R., Berlin, J., Allen, B., Bozic, I., Reiter, J.G., Nowak, M.A., Kinzler, K.W., Oliner, K.S. and Vogelstein, B. (2012) The Molecular Evolution of Acquired Resistance to Targeted EGFR Blockade in Colorectal Cancers. Nature, 486, 537-540. https://doi.org/10.1038/nature11219
|
[11]
|
Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Rich-ardson, T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., Martin, N.M., Jackson, S.P., Smith, G.C. and Ash-worth, A. (2005) Targeting the DNA Repair Defect in BRCA Mutant Cells as a Therapeutic Strategy. Nature, 434, 917-921. https://doi.org/10.1038/nature03445
|
[12]
|
Flaherty, K.T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L.V., Hassel, J.C., Rutkowski, P., Mohr, P., Dummer, R., Trefzer, U., Larkin, J.M., Utikal, J., Dreno, B., Nyakas, M., Middleton, M.R., Becker, J.C., Casey, M., Sherman, L.J., Wu, F.S., Ouellet, D., Martin, A.M., Patel, K. and Schadendorf, D. (2012) Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. The New England Journal of Medicine, 367, 107-114. https://doi.org/10.1056/NEJMoa1203421
|
[13]
|
Fong, P.C., Boss, D.S., Yap, T.A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O’Connor, M.J., Ash-worth, A., Carmichael, J., Kaye, S.B., Schellens, J.H. and de Bono, J.S. (2009) Inhibition of Poly(ADP-ribose) Poly-merase in Tumors from BRCA Mutation Carriers. The New England Journal of Medicine, 361, 123-134. https://doi.org/10.1056/NEJMoa0900212
|
[14]
|
Fukuoka, M., Wu, Y.L., Thongprasert, S., Sunpaweravong, P., Leong, S.S., Sriuranpong, V., Chao, T.Y., Nakagawa, K., Chu, D.T., Saijo, N., Duffield, E.L., Rukazenkov, Y., Speake, G., Jiang, H., Armour, A.A., To, K.F., Yang, J.C. and Mok, T.S. (2011) Biomarker Analyses and Final Overall Survival Results from a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib versus Carboplatin/Paclitaxel in Clinically Selected Patients with Advanced Non-Small-Cell Lung Cancer in Asia (IPASS). Journal of Clinical Oncology, 29, 2866-2874. https://doi.org/10.1200/JCO.2010.33.4235
|
[15]
|
Gerber, D.E. and Minna, J.D. (2010) ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time. Cancer Cell, 18, 548-551. https://doi.org/10.1016/j.ccr.2010.11.033
|
[16]
|
Hauschild, A., Grob, J.-J., Demidov, L.V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C.U., Miller, W.H., Kaempgen, E., MartAn-Algarra, S., Karaszewska, B., Mauch, C., Chiarion-Sileni, V., Martin, A.-M., Swann, S., Haney, P., Mirakhur, B., Guckert, M.E., Goodman, V. and Chapman, P.B. (2012) Dabrafenib in BRAF-Mutated Metastatic Melanoma: A Multicentre, Open-Label, Phase 3 Randomised Controlled Trial. The Lancet, 380, 358-365. https://doi.org/10.1016/S0140-6736(12)60868-X
|
[17]
|
Hennessy, B.T., Gonzalez-Angulo, A.M., Stemke-Hale, K., Gilcrease, M.Z., Krishnamurthy, S., Lee, J.S., Fridlyand, J., Sahin, A., Agarwal, R., Joy, C., Liu, W., Stivers, D., Baggerly, K., Carey, M., Lluch, A., Monteagudo, C., He, X., Weigman, V., Fan, C., Palazzo, J., Hortobagyi, G.N., Nolden, L.K., Wang, N.J., Valero, V., Gray, J.W., Perou, C.M. and Mills, G.B. (2009) Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics. Cancer Research, 69, 4116-4124. https://doi.org/10.1158/0008-5472.CAN-08-3441
|
[18]
|
Herbst, R.S., Heymach, J.V. and Lippman, S.M. (2008) Lung Cancer. The New England Journal of Medicine, 359, 1367-1380. https://doi.org/10.1056/NEJMra0802714
|
[19]
|
Jacobs, B., De Roock, W., Piessevaux, H., Van Oirbeek, R., Biesmans, B., De Schutter, J., Fieuws, S., Vandesompele, J., Peeters, M., Van Laethem, J.L., Humblet, Y., Penault-Llorca, F., De Hertogh, G., Laurent-Puig, P., Van Cutsem, E. and Tejpar, S. (2009) Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated with Cetuximab. Journal of Clinical Oncology, 27, 5068-5074.
|
[20]
|
Khambata-Ford, S., Garrett, C.R., Meropol, N.J., Basik, M., Harbison, C.T., Wu, S., Wong, T.W., Huang, X., Takimoto, C.H., Godwin, A.K., Tan, B.R., Krishnamurthi, S.S., Burris, H.A. III, Poplin, E.A., Hidalgo, M., Baselga, J., Clark, E.A. and Mauro, D.J. (2007) Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated with Cetuximab. Journal of Clinical Oncology, 25, 3230-3237. https://doi.org/10.1200/JCO.2006.10.5437
|
[21]
|
MacConaill, L.E. and Garraway, L.A. (2010) Clinical Implications of the Cancer Genome. Journal of Clinical Oncology, 28, 5219-5228. https://doi.org/10.1200/JCO.2009.27.4944
|
[22]
|
Maheswaran, S., Sequist, L.V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C.V., Inserra, E., Diederichs, S., Iafrate, A.J., Bell, D.W., Digumarthy, S., Muzikansky, A., Irimia, D., Set-tleman, J., Tompkins, R.G., Lynch, T.J., Toner, M. and Haber, D.A. (2008) Detection of Mutations in EGFR in Circu-lating Lung-Cancer Cells. The New England Journal of Medicine, 359, 366-377. https://doi.org/10.1056/NEJMoa0800668
|
[23]
|
Marchetti, A., Felicioni, L., Malatesta, S., Grazia Sciarrotta, M., Guetti, L., Chella, A., Viola, P., Pullara, C., Mucilli, F. and Buttitta, F. (2011) Clinical Features and Outcome of Patients with Non-Small-Cell Lung Cancer Harboring BRAF Mutations. Journal of Clinical Oncology, 29, 3574-3579. https://doi.org/10.1200/JCO.2011.35.9638
|
[24]
|
Metzker, M.L. (2009) Sequencing Technologies—The Next Generation. Nature Reviews Genetics, 11, 31-46. https://doi.org/10.1038/nrg2626
|
[25]
|
Miller, A.J. and Mihm, M.C. (2006) Melanoma. The New England Journal of Medicine, 355, 51-65. https://doi.org/10.1056/NEJMra052166
|
[26]
|
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., Bencardino, K., Cercek, A., Chen, C.T., Veronese, S., Zanon, C., Sartore-Bianchi, A., Gambacorta, M., Gallicchio, M., Vakiani, E., Boscaro, V., Medico, E., Weiser, M., Siena, S., Di Nicolantonio, F., Solit, D. and Bardelli, A. (2012) Emergence of KRAS Mutations and Acquired Resistance to Anti-EGFR Therapy in Colorectal Cancer. Nature, 486, 532-536. https://doi.org/10.1038/nature11156
|
[27]
|
Mok, T.S., Wu, Y.L., Thongprasert, S., Yang, C.H., Chu, D.T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J.J., Chewaskulyong, B., Jiang, H., Duffield, E.L., Watkins, C.L., Armour, A.A. and Fukuoka, M. (2009) Gefitinib or Carboplatin-Paclitaxel in Pulmonar Adenocarcinoma. The New England Journal of Medicine, 361, 947-957. https://doi.org/10.1056/NEJMoa0810699
|
[28]
|
Normanno, N., Bianco, C., De Luca, A., Maiello, M.R. and Salomon, D.S. (2003) Target-Based Agents against ErbB Receptors and Their Ligands: A Novel Approach to Cancer Treatment. Endocrine-Related Cancer, 10, 1-21.
|
[29]
|
Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M.R., Carotenuto, A., De Feo, G., Caponigro, F. and Salomon, D.S. (2006) Epidermal Growth Factor Receptor (EGFR) Signaling in Cancer. Gene, 366, 2-16. https://doi.org/10.1016/j.gene.2005.10.018
|
[30]
|
Normanno, N., Morabito, A., De Luca, A., Piccirillo, M.C., Gallo, M., Maiello, M.R. and Perrone, F. (2009) Target-Based Therapies in Breast Cancer: Current Status and Future Perspectives. Endocrine-Related Cancer, 16, 675-702.
|
[31]
|
Normanno, N., Tejpar, S., Morgillo, F., De Luca, A., Van Cutsem, E. and Ciardiello, F. (2009) Implications for KRAS Status and EGFR-Targeted Therapies in Metastatic CRC. Endocrine-Related Cancer, 6, 519-527.
|
[32]
|
Normanno, N., Pinto, C., Castiglione, F., Bardelli, A., Gambacorta, M., Botti, G., Nappi, O., Siena, S., Ciardiello, F., Taddei, G. and Marchetti, A. (2011) KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment. PLoS ONE, 6, e29146.
|
[33]
|
O’Donovan, P.J. and Livingston, D.M. (2010) BRCA1 and BRCA2: Breast/Ovarian Cancer Susceptibility Gene Products and Participants in DNA Double-Strand Break Repair. Carcinogenesis, 31, 961-967. https://doi.org/10.1093/carcin/bgq069
|
[34]
|
Pao, W. and Hutchinson, K.E. (2012) Chipping away at the Lung Cancer Genome. Nature Medicine, 18, 349-351. https://doi.org/10.1038/nm.2697
|